Eni SpA vs Revolution Medicines Inc. Common Stock — how do they compare? Eni SpA trades at $56.11 (market cap $79.81B), while Revolution Medicines Inc. Common Stock trades at $191.04 (market cap $40.32B). The key difference: Eni SpA is the larger of the two by market cap, and Eni SpA pays a 4.39% dividend while Revolution Medicines Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eni SpA for 53 Days and Revolution Medicines Inc. Common Stock for 0 Days on average.
| E | RVMD | |
|---|---|---|
Market Cap | $79.81B | $40.32B |
Volume | 365,912 | 4,855,734 |
Sector | Energy | Health |
52-Week High | $57.61 | $221.15 |
52-Week Low | $34.03 | $47.50 |
Typical Hold Time | 53 Days | 0 Days |
Enterprise Value | $104.34B | $37.02B |
Dividend Yield | 4.39% | — |
Signals from Pluang's Aura AI — not financial advice
Eni (E) trades at $56.09, up 3.95% on the day, with mixed technical signals showing bearish moving averages but oversold short-term RSI. Fundamentally, the company shows attractive valuation metrics with P/E of 12.87 and EV/EBITDA of 4.18, though revenue has declined from $132.5B in 2022 to $82.2B in 2025. Recent news highlights strategic initiatives including humanoid robotics partnerships and fuel discount programs.
The stock presents value opportunity with strong cash flow generation and dividend yield, but faces headwinds from declining revenue trends and recent earnings misses. Analyst consensus leans cautious with 62% hold ratings, suggesting patience required for operational turnaround despite attractive valuation multiples.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →Revolution Medicines develops precision medicines for cancer. Its programs focus on targeting RAS-driven cancers and related signaling pathways.
Read more on RVMD →